Back HIV/AIDS HIV/AIDS Topics HIV Treatment

AIDS 2016: Efavirenz Appears Associated with Elevated Suicide Risk in START Trial

Participants in the START treatment-timing trial who took antiretroviral regimens containing efavirenz had an increased risk of suicidal and self-injuring behavior than those not using efavirenz, though the number of events was small and the effect was mainly seen among people with a prior psychiatric diagnosis, according to research presented at the 21st International AIDS Conference last month in Durban.

alt

Read more:

AIDS 2016: International AIDS Society Releases New HIV Cure Research Strategy

The International AIDS Society (IAS) released an update to its strategy to guide HIV cure research. The strategy, authored by the leading researchers in the field, was published in the July 11 online edition of Nature Medicine and discussed at the IAS Towards an HIV Cure Symposium preceding the 21st International AIDS Conference last month in Durban.alt

Read more:

Coverage of 21st International AIDS Conference (AIDS 2016)

HIVandHepatitis.com coverage of the 21st International AIDS Conference (AIDS 2016), held July 18-22, in Durban, South Africa.

Conference highlights include PrEP and other biomedical HIV prevention, HIV cure research, experimental antiretroviral therapy, and access to treatment and prevention for key affected populations.

Full listing by topic

AIDS 2016 website

7/28/16

alt

AIDS 2016: Seeking a Cure, Doctors Document Bone Marrow Transplant Recipients with HIV

The "Berlin patient," Timothy Ray Brown, has now survived 7 years off antiretroviral therapy (ART) with no sign of HIV reappearing in his body, and as time passes his position as "the person cured of HIV" becomes more secure. However, participants at the 2016 Towards a Cure Symposium, held in advance of the recent 21st International AIDS Conference (AIDS 2016) in Durban, heard about the work of a consortium of physicians and researchers who are searching for, and documenting, the fates of patients with HIV who, like Brown, have been given stem cell transplants for cancer, in an effort to abolish Brown’s distinction as the only person to be cured of HIV.

alt

Read more:

AIDS 2016: START Analysis Looks at Who Benefits Most from Immediate HIV Treatment

Starting antiretroviral therapy (ART) soon after HIV diagnosis led to better outcomes than delayed treatment in all population subgroups in the START trial, researchers reported at the 21st International AIDS Conference (AIDS 2016) last week in Durban. But some people saw greater risk reductions, including those over age 50, those with a lower CD4:CD8 ratio and higher viral load, and those with cardiovascular risk factors.

alt

Read more:

AIDS 2016: HIV Viral Load Pilot Study Shows Roll-Out Will Depend on an Educated Workforce

For viral load testing to prevent HIV treatment failure, drug resistance, and onward transmission, treatment programs will need to invest in better record-keeping and clinic procedures, human resources, demand creation, and decentralization of second-line treatment provision, a large pilot study of viral load test provision in southern Africa has found. Findings were presented last month at the 21st International AIDS Conference (AIDS 2016) in Durban.

alt

Read more:

AIDS 2016: Starting Treatment on the Day of HIV Diagnosis Improves Outcomes

Interventions to improve linkage to HIV care and retention in treatment which speed up the start of antiretroviral therapy (ART) or provide intensive support to people before starting treatment produce better retention than standard practices, researchers reported at the 21st International AIDS Conference (AIDS 2016) last week in Durban.

alt

Read more: